Downstream processing

Microcarrier Market Poised to Reach $3.43 Billion by 2030: Driving Advances in Biopharmaceuticals and Vaccine Production - ResearchAndMarkets.com

Retrieved on: 
Thursday, October 19, 2023

The global Microcarrier Market is poised to achieve a substantial valuation of US$ 3.43 billion by 2030, according to a comprehensive market analysis.

Key Points: 
  • The global Microcarrier Market is poised to achieve a substantial valuation of US$ 3.43 billion by 2030, according to a comprehensive market analysis.
  • The Microcarrier Market is experiencing significant growth, driven by the need to enhance vaccine production yields, reduce costs, and address a wide range of diseases.
  • These beads provide a flexible platform for cell attachment and growth, facilitating the production of biopharmaceuticals, vaccines, and cell-based therapies.
  • The United States stands out in the Microcarrier Market, known for its innovation and technological advancements.

Pharmaceutical and Biotechnology Companies Lead the Microcarrier Market with Innovation and R&D Investments

Retrieved on: 
Monday, October 16, 2023

The global Microcarrier Market is poised to achieve a substantial valuation of US$ 3.43 billion by 2030, according to a comprehensive market analysis.

Key Points: 
  • The global Microcarrier Market is poised to achieve a substantial valuation of US$ 3.43 billion by 2030, according to a comprehensive market analysis.
  • Pharmaceutical and biotechnology companies lead the Microcarrier Market, relying extensively on microcarriers for various applications.
  • Continuous investments in research and development, along with innovation in microcarrier technology, further bolster the demand for microcarriers.
  • The United States stands out in the Microcarrier Market, known for its innovation and technological advancements.

Dotmatics Releases Powerful Enhancements to its Biology Solution to Help Accelerate the Research and Discovery of Life-Improving Therapies

Retrieved on: 
Wednesday, September 13, 2023

BOSTON, Sept. 13, 2023 /PRNewswire/ -- Dotmatics, a leader in R&D scientific software connecting science, data, and decision-making, today announced the availability of the latest version of its Biology Solution, an end-to-end biologics data management and analysis tool designed to help R&D leaders get more insight from their data, faster. The Biology Solution offers common workflows for scientists who work in biopharma, industrial biotech, and AgTech to accelerate new product development, simplify project management, and reduce the complexities of research IT infrastructure. The new version includes expanded functionality for molecular cloning and vector design, protein production, new biologics registration, and more.

Key Points: 
  • The Biology Solution offers common workflows for scientists who work in biopharma, industrial biotech, and AgTech to accelerate new product development, simplify project management, and reduce the complexities of research IT infrastructure.
  • The Biology Solution is the latest update to a suite of recently released Dotmatics Solutions, which are pre-configured packages of capabilities and workflows to support specific scientific disciplines.
  • In addition, the Biology Solution reduces time to implementation, enhances the customer's drug discovery capabilities, and reduces internal data transfer requirements.
  • Enterprise includes access to Dotmatics' ELN and Data Discovery capabilities to support a broad array of biologics discovery.

SK pharmteco doubles viral vector production capacity in Europe

Retrieved on: 
Friday, June 23, 2023

SK pharmteco announced on June 22nd that Yposkesi, its commercial viral vector manufacturing subsidiary for C&GT in France, successfully completed the construction of its second industrial bioproduction site for C&GT manufacturing.

Key Points: 
  • SK pharmteco announced on June 22nd that Yposkesi, its commercial viral vector manufacturing subsidiary for C&GT in France, successfully completed the construction of its second industrial bioproduction site for C&GT manufacturing.
  • It is one of the few in Europe to operate two bioproduction platforms for the most used viral vectors: Adeno Associated Virus (AAV) and Lentiviral Vector (LV).
  • In 2019, SK Inc. established SK pharmteco, a globally integrated contract development and manufacturing organization (CDMO) for pharmaceuticals.
  • SK pharmteco operates seven production facilities and five R&D centers strategically located across the United States, Europe, and Korea.

SK pharmteco doubles viral vector production capacity in Europe

Retrieved on: 
Friday, June 23, 2023

SK pharmteco announced on June 22nd that Yposkesi, its commercial viral vector manufacturing subsidiary for C&GT in France, successfully completed the construction of its second industrial bioproduction site for C&GT manufacturing.

Key Points: 
  • SK pharmteco announced on June 22nd that Yposkesi, its commercial viral vector manufacturing subsidiary for C&GT in France, successfully completed the construction of its second industrial bioproduction site for C&GT manufacturing.
  • It is one of the few in Europe to operate two bioproduction platforms for the most used viral vectors: Adeno Associated Virus (AAV) and Lentiviral Vector (LV).
  • In 2019, SK Inc. established SK pharmteco, a globally integrated contract development and manufacturing organization (CDMO) for pharmaceuticals.
  • SK pharmteco operates seven production facilities and five R&D centers strategically located across the United States, Europe, and Korea.

Innovations in Downstream Processing, Electric Hydraulic Fracturing, Oil Spill Remediation & Digitization in the Oil & Gas Industry - ResearchAndMarkets.com

Retrieved on: 
Wednesday, November 23, 2022

The "Innovations in Downstream Processing, Electric Hydraulic Fracturing, Oil Spill Remediation & Digitization in the Oil & Gas Industry" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Innovations in Downstream Processing, Electric Hydraulic Fracturing, Oil Spill Remediation & Digitization in the Oil & Gas Industry" report has been added to ResearchAndMarkets.com's offering.
  • The TOE also covers innovations based on the use of proprietary and eco-friendly reagents for oil wastewater and sludge treatment.
  • The Oil and Gas TOE provides intelligence on innovations pertaining to technologies, products, and processes, along with strategic insights, in the upstream and downstream processes in the oil and gas industry.
  • 1 Innovations in Downstream Processing, Electric Hydraulic Fracturing, Oil Spill Remediation & Digitization in the Oil & Gas Industry
    Nanofiltration Technology Enables Sustainable and More Effective Chemical Separation in Oil & Gas, Chemical, and Petrochemical Industry
    Mesoporization Technology Enhances the Performance of the Zeolite Catalysts Used in Oil & Gas, and Chemical Industry

Global Viral Vector & Plasmid DNA Manufacturing Market Report 2022: Facility Expansion for Cell and Gene Therapies Presents Opportunities - ResearchAndMarkets.com

Retrieved on: 
Tuesday, September 20, 2022

The Global Viral Vector & Plasmid DNA Manufacturing Market is segmented based on Cell Line, Type, Transfection, Indication, Workflow, Application, and Geography.

Key Points: 
  • The Global Viral Vector & Plasmid DNA Manufacturing Market is segmented based on Cell Line, Type, Transfection, Indication, Workflow, Application, and Geography.
  • The report presents a detailed Ansoff matrix analysis for the Global Viral Vector & Plasmid DNA Manufacturing Market.
  • The Global Viral Vector & Plasmid DNA Manufacturing Market is analyzed using the Ansoff Matrix to provide the best approaches a company can take to improve its market position.
  • The report offers a comprehensive evaluation of the Global Viral Vector & Plasmid DNA Manufacturing Market.

Pharming announces commitment to build a new downstream manufacturing facility for RUCONEST®

Retrieved on: 
Thursday, November 19, 2020

LEIDEN, The Netherlands, Nov. 19,2020 /PRNewswire/ --Pharming Group N.V. (Euronext Amsterdam: PHARM) announces it has committed to building a new facility to expand the Company's downstream processing capacity for its lead product, RUCONEST (recombinant C1 esterase inhibitor (rhC1INH)).

Key Points: 
  • LEIDEN, The Netherlands, Nov. 19,2020 /PRNewswire/ --Pharming Group N.V. (Euronext Amsterdam: PHARM) announces it has committed to building a new facility to expand the Company's downstream processing capacity for its lead product, RUCONEST (recombinant C1 esterase inhibitor (rhC1INH)).
  • The downstream processing facility will include the purification, filtration and concentration of the starting material.
  • Pivot Park is also the location of BioConnection B.V., Pharming's contracted fill and finish facility, in which Pharming holds a minority stake.
  • It is the first new building on the campus and CEO Drees hopes many more will follow.

Repligen and Navigo Proteins Announce Achievement of Key Milestone in Developing an Affinity Resin for the Purification of COVID-19 Vaccines

Retrieved on: 
Thursday, October 1, 2020

The affinity resin aims to provide end users with a rapid, high purity capture step, decreasing processing time and potentially improving overall yield in the manufacturing of critical COVID-19 vaccines.

Key Points: 
  • The affinity resin aims to provide end users with a rapid, high purity capture step, decreasing processing time and potentially improving overall yield in the manufacturing of critical COVID-19 vaccines.
  • Repligen anticipates that the final resin product will be commercially available in early 2021.
  • Navigo Proteins is a premier protein engineering company, specialized in creating novel affinity ligands for PRECISION CAPTURING and PRECISION TARGETING.
  • Navigo works with renowned partners to convert its affinity ligands into ready-to-use, GMP-compliant affinity resins for commercial downstream processing.

Downstream Processing Market Size, Share & Trends Analysis Report By Product, By Technique, By Application, By Region And Segment Forecasts, 2020 - 2027

Retrieved on: 
Thursday, March 5, 2020

Downstream Processing Market Size, Share & Trends Analysis Report By Product (Chromatography Systems, Filters), By Technique (Cell Disruption, Concentration), By Application, By Region, And Segment Forecasts, 2020 - 2027

Key Points: 
  • Downstream Processing Market Size, Share & Trends Analysis Report By Product (Chromatography Systems, Filters), By Technique (Cell Disruption, Concentration), By Application, By Region, And Segment Forecasts, 2020 - 2027
    The global downstream processing market size is expected to reach USD 49.9 billion by 2027, expanding at a CAGR of 13.1%.
  • The downstream processing technology is being increasingly used in both laboratory and industrial-scale bioprocessing applications owing to a growing demand for biologics, which is anticipated to boost industry growth.
  • In addition, the advantages offered by the use of single-use bioprocessing equipment are also expected to drive the growth of the market.
  • Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.